Tocotrienol build-up in tumours ‘critical’ for anti-cancer benefits: Study

By Stephen Daniells

- Last updated on GMT

Tocotrienols, members of the vitamin E family, may exert their anti-cancer benefits by accumulating in cancer cells and delaying tumour growth, says a new study from Japan.

Both gamma- and delta-tocotrienols may accumulate in cancer cells, and promote the death of the tumours, according to data from in vitro​ and in vivo​ studies by researchers from Kyushu University.

The potential anti-cancer benefits of tocotrienols are not new, but the Japanese researcher claim that their study is the first to show accumulation of the compounds in cancer cells.

“These results, to our knowledge, are the first demonstration of specific accumulation of gamma-tocotrienol and delta-tocotrienol in tumours and suggest that tocotrienols accumulation is critical for the anti-tumour activities of tocotrienols,”​ wrote lead author Yuhei Hiura in the The Journal of Nutritional Biochemistry​.

The vitamin E family

There are eight forms of vitamin E: four tocopherols (alpha, beta, gamma, delta) and four tocotrienols (alpha, beta, gamma, delta). Alpha-tocopherol is the main source found in supplements and in the European diet, while gamma-tocopherol is the most common form in the American diet.

Tocotrienols (TCT) are only minor components in plants, although several sources with relatively high levels include palm oil, cereal grains and rice bran.

While the majority of research on vitamin E has focused on alpha-Toc, studies into tocotrienols account for less than one per cent of all research into vitamin E.

New study

The Japanese researchers studied the effects of gamma- and delta-tocotrienol on mouse cancer cells (murine hepatoma MH134) both in vitro​ and in vivo​. For the cell study, the tumour cells were cultured in the tocotrienols, and they found that the delta-version inhibited cell growth more than the gamma-type. This was related to an induction of apoptosis (programmed cell death).

For the animal studies, the researchers used C3H/HeN mice and implanted the tumour cells. The animals were then fed a normal diet, or the diet supplemented with 0.1 per cent gamma-tocotrienol or 0.1 per cent delta-tocotrienol for four weeks.

At the end of the study, a significant delay in tumour growth was observed for both groups supplemented with the tocotrienols. No effects on body weight were recorded.

“Intriguingly, we found that tocotrienols was detected in tumour, but not in normal tissues,”​ wrote the researchers.

In terms of the added that the tocotrienols had no effect on levels of immunoglobulin levels in the animals, suggesting that the tocotrienols’ potential anti-cancer benefits were not related to immune function, “and that the anti-tumour effect may be due to the directeffect of T3 on tumour cells”​, they said.

“In conclusion, our results suggested that accumulation is critical for the anti-tumour activity of tocotrienols.”

Source: The Journal of Nutritional Biochemistry​ Published online ahead of print, doi: 10.1016/j.jnutbio.2008.06.004“Specific accumulation of γ- and δ-tocotrienols in tumor and their antitumor effect ​in vivo​ Authors: Y. Hiura, H. Tachibana, R. Arakawa, N. Aoyama, M. Okabe, M. Sakai, K. Yamada

Related news

Show more

Related products

show more

Unlock sensory innovation with AromatiQ™ technology

Unlock sensory innovation with AromatiQ™ technology

Content provided by Lonza | 20-Sep-2024 | Product Brochure

With 70% of consumers willing to pay a premium for a more enjoyable and memorable supplement experience, Lonza’s new AromatiQ™ technology enables brands...

Your guide to nutritional care innovation

Your guide to nutritional care innovation

Content provided by dsm-firmenich | 22-Aug-2024 | Insight Guide

The medical nutrition market is primed for innovation due to aging populations, chronic diseases, nutrition awareness and scientific advances. Our comprehensive...

Related suppliers

Follow us

Products

View more

Webinars